Log In
BCIQ
Print this Print this
 

ApoStream

  Manage Alerts
Collapse Summary General Information
Company ApoCell Inc.
DescriptionDetection device using dielectrophoresis field flow fractionation to isolate and recover circulating tumor cells (CTCs)
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsEarly detection of hepatocellular carcinoma (HCC); Identify EGFR mutations in circulating tumor cells (CTCs) from non-small cell lung cancer (NSCLC) patients
Regulatory Designation
PartnerCancer Genetics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$5.3M

0

0


 Deals Details
Get a free BioCentury trial today